Kanglexin accelerates diabetic wound healing by promoting angiogenesis via FGFR1/ERK signaling

Volume: 132, Pages: 110933 - 110933
Published: Dec 1, 2020
Abstract
Diabetic foot is one of the main causes of non-traumatic amputation. However, there is still lack of effective drugs to treat diabetic foot in clinical practice. Kanglexin (KLX) is a new anthraquinone compound with cardiovascular protective effects. Here we report that KLX accelerates diabetic wound healing by promoting angiogenesis via FGFR1/ERK signaling. Firstly, KM mice were injected (ip) with streptozocin to establish type 1 diabetic model....
Paper Details
Title
Kanglexin accelerates diabetic wound healing by promoting angiogenesis via FGFR1/ERK signaling
Published Date
Dec 1, 2020
Volume
132
Pages
110933 - 110933
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.